Oncological outcomes in non-seminomatous testicular tumors and residual mass after cisplatin-based chemotherapy
Objective: The aim of our study is to describe the progression-free survival (PFS) in patients with clinical stage (CS) II and III NSGCT with an RM after primary or secondary CT with negative serum markers (NSM). A residual mass (RM) in non-seminomatous germ cell tumors (NSGCT) after chemotherapy (C...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedad Colombiana de Urología
2024-04-01
|
| Series: | Urología Colombiana |
| Subjects: | |
| Online Access: | https://www.urologiacolombiana.com/frame_eng.php?id=43 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832572860894281728 |
|---|---|
| author | María A. Ocampo-Gómez María C. Moreno-Matson David Ruiz-Londoño Marino Cabrera Rodolfo Varela |
| author_facet | María A. Ocampo-Gómez María C. Moreno-Matson David Ruiz-Londoño Marino Cabrera Rodolfo Varela |
| author_sort | María A. Ocampo-Gómez |
| collection | DOAJ |
| description | Objective: The aim of our study is to describe the progression-free survival (PFS) in patients with clinical stage (CS) II and III NSGCT with an RM after primary or secondary CT with negative serum markers (NSM). A residual mass (RM) in non-seminomatous germ cell tumors (NSGCT) after chemotherapy (CT) is defined as a mass >1 cm in greatest diameter. The preferred treatment for RM is retroperitoneal lymph node dissection (RPLND), with a cure rate greater than 80%. Methods: We identified 60 patients with NSGCT, RM, and NSM between 2007 and 2020. Data regarding clinical and oncological outcomes as well as pathological information were obtained in a retrospective fashion from our electronic database. Results: A total of 60 patients were included. 50% of cases were CS II, and 50% CS III. About 90% of the patients had undergone RPLND. Teratoma was found in 73.6% of these patients. PFS and OS were better in CS II patients, compared to CS III. The patients treated with observation were found to have a shorter PFS compared to patients who underwent RPLND. Patients with viable tumors after RPLND had shorter OS compared to patients with teratoma and fibrosis. Conclusions: RPLND continues to be the treatment of choice to patients with RM after CT and NSM.
|
| format | Article |
| id | doaj-art-1ce0b1b23af942098ca284ef7c3aec64 |
| institution | Kabale University |
| issn | 0120-789X |
| language | English |
| publishDate | 2024-04-01 |
| publisher | Sociedad Colombiana de Urología |
| record_format | Article |
| series | Urología Colombiana |
| spelling | doaj-art-1ce0b1b23af942098ca284ef7c3aec642025-02-02T06:40:12ZengSociedad Colombiana de UrologíaUrología Colombiana0120-789X2024-04-01332Oncological outcomes in non-seminomatous testicular tumors and residual mass after cisplatin-based chemotherapyMaría A. Ocampo-Gómez0María C. Moreno-Matson1David Ruiz-Londoño2Marino Cabrera3Rodolfo Varela4Department of Urology, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, ColombiaDepartment of Urology, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, ColombiaDepartment of Urology, Colombian National Cancer Institute. Bogotá, ColombiaDepartment of Urology, Colombian National Cancer Institute. Bogotá, ColombiaDepartment of Urology, Colombian National Cancer Institute. Bogotá, ColombiaObjective: The aim of our study is to describe the progression-free survival (PFS) in patients with clinical stage (CS) II and III NSGCT with an RM after primary or secondary CT with negative serum markers (NSM). A residual mass (RM) in non-seminomatous germ cell tumors (NSGCT) after chemotherapy (CT) is defined as a mass >1 cm in greatest diameter. The preferred treatment for RM is retroperitoneal lymph node dissection (RPLND), with a cure rate greater than 80%. Methods: We identified 60 patients with NSGCT, RM, and NSM between 2007 and 2020. Data regarding clinical and oncological outcomes as well as pathological information were obtained in a retrospective fashion from our electronic database. Results: A total of 60 patients were included. 50% of cases were CS II, and 50% CS III. About 90% of the patients had undergone RPLND. Teratoma was found in 73.6% of these patients. PFS and OS were better in CS II patients, compared to CS III. The patients treated with observation were found to have a shorter PFS compared to patients who underwent RPLND. Patients with viable tumors after RPLND had shorter OS compared to patients with teratoma and fibrosis. Conclusions: RPLND continues to be the treatment of choice to patients with RM after CT and NSM. https://www.urologiacolombiana.com/frame_eng.php?id=43Non seminomatous testicular tumor. Residual mass. Cisplatin based chemotherapy. |
| spellingShingle | María A. Ocampo-Gómez María C. Moreno-Matson David Ruiz-Londoño Marino Cabrera Rodolfo Varela Oncological outcomes in non-seminomatous testicular tumors and residual mass after cisplatin-based chemotherapy Urología Colombiana Non seminomatous testicular tumor. Residual mass. Cisplatin based chemotherapy. |
| title | Oncological outcomes in non-seminomatous testicular tumors and residual mass after cisplatin-based chemotherapy |
| title_full | Oncological outcomes in non-seminomatous testicular tumors and residual mass after cisplatin-based chemotherapy |
| title_fullStr | Oncological outcomes in non-seminomatous testicular tumors and residual mass after cisplatin-based chemotherapy |
| title_full_unstemmed | Oncological outcomes in non-seminomatous testicular tumors and residual mass after cisplatin-based chemotherapy |
| title_short | Oncological outcomes in non-seminomatous testicular tumors and residual mass after cisplatin-based chemotherapy |
| title_sort | oncological outcomes in non seminomatous testicular tumors and residual mass after cisplatin based chemotherapy |
| topic | Non seminomatous testicular tumor. Residual mass. Cisplatin based chemotherapy. |
| url | https://www.urologiacolombiana.com/frame_eng.php?id=43 |
| work_keys_str_mv | AT mariaaocampogomez oncologicaloutcomesinnonseminomatoustesticulartumorsandresidualmassaftercisplatinbasedchemotherapy AT mariacmorenomatson oncologicaloutcomesinnonseminomatoustesticulartumorsandresidualmassaftercisplatinbasedchemotherapy AT davidruizlondono oncologicaloutcomesinnonseminomatoustesticulartumorsandresidualmassaftercisplatinbasedchemotherapy AT marinocabrera oncologicaloutcomesinnonseminomatoustesticulartumorsandresidualmassaftercisplatinbasedchemotherapy AT rodolfovarela oncologicaloutcomesinnonseminomatoustesticulartumorsandresidualmassaftercisplatinbasedchemotherapy |